Marinomed Biotech AG announces top line results of Phase III study for Budesolv
By: Marinomed Biotech AG
As announced, the complete Phase III study with detailed results is expected and will be published by the end of the second quarter of 2019 at the latest.
Marinosolv®and the flagship product Budesolv
Marinomed has succeeded in increasing the bioavailability of hardly soluble compounds to treat sensitive tissues such as nose and eyes via the Marinosolv®technology platform. The platform's flagship product is Budesolv, a nasal spray for the treatment of allergic rhinitis.
About Marinomed Biotech AG
Marinomed Biotech AG is a biopharmaceutical company with headquarters in Vienna and has been listed in the Prime Market of the Vienna Stock Exchange since February 1, 2019. The company focuses on the development of innovative products based on patent-protected technology platforms in the field of respiratory and ophthalmological diseases. The Marinosolv®technology platform increases the efficacy of hardly soluble compounds for the treatment of sensitive tissues such as the eyes and nose. The Carragelose®platform comprises innovative patent-protected products targeting viral infections of the respiratory tract. Carragelose®is used in nasal sprays, throat sprays and lozenges, which are sold via international partners in over 30 countries worldwide. Further information is available at: www.marinomed.com.
For further enquiries contact:
Dr. Eva Prieschl-Grassauer
Chief Scientific Officer, Marinomed
Veterinärplatz 1, 1210 Wien, Austria
T +43 (0)1 250 77 446
Managing Partner, Metrum Communications
T +43 (0) 1 504 69 87 331
Marinomed Biotech AG